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Abstract 
Three novel gallium(III) and iron(III) complexes with L-proline-thiosemicarbazone hybrids, 
namely [GaCl(L-Pro-FTSC–2H)]·0.7H2O·0.5CH3OH (1·0.7H2O·0.5CH3OH), [GaCl(dm-L-Pro-
FTSC–2H)]·0.4H2O (2·0.4H2O) and [FeCl(L-Pro-FTDA‒H)]Cl (3) were synthesised and 
comprehensively characterised by spectroscopic methods (1H, 13C NMR, UV−vis), ESI mass 
spectrometry and X-ray crystallography. The complexes are soluble in biological media to allow 
for assaying their antiproliferative activity. The complexes were tested in three human cancer 
cell lines, namely HeLa, A549 (non-small cell lung cancer), LS174 and nontumorigenic MRC5. 
Complex formation equilibrium processes of L-Pro-FTSC with gallium(III), iron(II) and iron(II) 
ions were investigated in solution. The formation of mono-ligand iron(II) and gallium(III) 
complexes with pentadentate ligands and relatively low aqueous solution stability was found. 
Between iron(III) and the ligands, a redox reaction takes place via the oxidative cyclisation of the 
thiosemicarbazones.  
 
Keywords: Thiosemicarbazones, Gallium(III), Iron(III), Antiproliferative activity 
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1. Introduction  
Gallium(III) is the second metal ion after platinum(II) which is applied in anticancer therapy. 
Gallium(III) nitrate showed anticancer activity in bladder cancer and non-Hodgkin’s lymphoma 
in clinical trials1,2,3,4,5 and is currently approved for the treatment of cancer related 
hypercalcemia.6 Gallium(III) strongly resembles iron(III) as both ions have comparable ionic 
radii. In fact, this also explains the biological activities of gallium(III): it is believed that the 
human body cannot distinguish between iron(III) and gallium(III), therefore both use the same 
transport pathways and are bound to the same proteins, with the difference that gallium(III) is 
virtually irreducible under physiological conditions.7 Many malignancies and in general, fast 
dividing tissues have an enhanced demand for iron, which leads to a characteristic 
overexpression of transferrin receptors on the cell surface in many cancer types.8,9,10 
Consequently gallium(III), which is almost exclusively bound to transferrin in the human blood 
plasma,11 accumulates in many cancers to a greater amount than in normal tissues. 67Ga is 
therefore suitable for tumor detection.12 
Iron is necessary for the synthesis of ribonucleotide reductase (RNR), an enzyme that performs 
the rate determining step of DNA synthesis, namely, the reduction of ribonucleotides to the 
corresponding deoxyribonucleotides. It contains a diferric tyrosyl radical cofactor which is 
essential for its function.13,14 It is known that gallium(III) is able to replace the iron(III) ions in 
RNR and thereby inhibits its activity.15 A problem in the use of simple gallium salts, such as 
gallium(III) nitrate for cancer treatment is their fast hydrolysis in the human blood stream, 
leading to the precipitation of sparingly soluble gallium(III) hydroxides and consequently a low 
bioavailability.7,16 This led to the development of more stable gallium complexes, namely 
gallium(III) maltolate, tris(3-hydroxy-2-methyl-4H-pyran-4-onato)gallium(III) and tris(8-
quinolinolato)gallium(III) (KP46) which are currently under clinical investigation.17 Gallium 
complexes with thiosemicarbazone and thiocarbohydrazone ligands are also of interest for 
anticancer therapy.18 Thiosemicarbazones (TSCs) are potent metal chelators with a broad 
spectrum of biological activity.19,20,21,22,23,24 Tibione or p-acetylaminobenzaldehyde TSC was 
used as a drug against tuberculosis.25 Their anticancer activity was discovered in the 1960s when 
2-formylpyridine TSC was tested in a leukemia bearing mouse model.26 The best studied TSC to 
date is 3-aminopyridine-2-carboxaldehyde TSC or Triapine, which was evaluated in several 
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clinical phase I and II trials. Overall, Triapine is inactive against solid tumors but shows 
promising results against leukemia and other blood malignancies.27,28,29,30,31,32,33,34,35,36 TSCs are 
inhibitors of the enzymes RNR and Topoisomerase IIα, both of which are good targets for 
anticancer therapy, since they are essential for cell division.14,37,38,39,40,41,42 Metal complexation 
plays an important role in the activity of TSCs. In the case of Triapine and related RNR 
inhibiting TSCs, for example, it is not the free ligand precursors but their in vivo formed iron(II) 
complex that is the active species. The iron(II) bis(Triapine) complex is able to reduce a diferric 
tyrosyl radical in the R2 subunit of RNR, which quenches the enzyme activity.43,44,45,46 On the 
other hand copper(II) complexation of Topoisomerase IIα inhibiting TSCs, leading to square-
planar complexes, enhances their activity markedly.47 A possible synergistic effect in RNR 
inhibition is the rationale for the synthesis of gallium(III)-TSC complexes. An increased 
cytotoxicity of gallium(III)-TSC complexes has been observed when compared to the free 
ligands (ligand precursors) and the corresponding iron(III)-TSC complexes, although the 
iron(III)-TSC complexes quenched the RNRs tyrosyl radical faster than its gallium(III) 
counterparts.48 An explanation for this might be that the Ga(III)-TSC complex hydrolyzes within 
the cell and the free TSC ligand gets released, which in turn chelates intracellular iron and 
possibly also sequesters iron from the RNR enzyme.45  
 
Herein we report on the synthesis, spectroscopic and X-ray diffraction studies, as well as 
evaluation of antiproliferative activity of two gallium(III) and one iron(III) complex resulting 
from reactions of gallium(III) and iron(II) salts/complexes with L-proline-thiosemicarbazone 
hybrids L-Pro-FTSC and dm-L-Pro-FTSC (Chart 1). In addition, solution equilibrium studies of 
the complexation of L-Pro-FTSC with gallium(III), iron(II) and iron(III) in aqueous solution 
have been performed by 1H NMR spectroscopy, pH-potentiometry and UV‒vis 
spectrophotometry. Speciation data were used to rationalize the cytotoxicity of the compounds 
tested in human cancer cell lines. 
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Chart 1. Complexes studied in this work. 
 
 
2. Experimental 
2.1. Materials and Methods 
L-Pro-FTSC,49,50 dm-L-Pro-FTSC51 and tetrapyridino-ferrous chloride52 were prepared according 
to published protocols. Solvents were dried using standard techniques and/or degassed using the 
traditional freeze-pump-thaw method (three cycles) if needed.53 KOH, GaCl3, KSCN, EDTA, 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and N-cyclohexyl-2-
aminoethanesulfonic acid (CHES) were purchased from Sigma-Aldrich and HCl, KCl, KMnO4, 
Fe, FeCl3 were Reanal products. The iron(II) stock solution was obtained from fine Fe powder 
dissolved in a known amount of HCl solution under a purified, strictly oxygen-free argon 
atmosphere, then filtered, stored and used under anaerobic conditions. KSCN solution was used 
to check the absence of iron(III) traces in the iron(II) solution. The concentration of the iron(II) 
stock solution was determined by permanganometric titrations under acidic conditions. GaCl3 
and FeCl3 stock solution were prepared by dissolving the appropriate amount of the metal 
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chlorides in a known amount of HCl and their concentrations were determined by 
complexometry via the EDTA complexes. Accurate strong acid content of the metal stock 
solutions were determined by pH-potentiometric titrations. 
 
2.2. Synthesis of Complexes 
2.2.1. [GaCl(L-Pro-FTSC–2H)]·0.7H2O·0.5CH3OH, 1·0.7H2O·0.5CH3OH  
To a solution of L-Pro-FTSC (0.10 g, 0.32 mmol) in dry methanol (5 mL) was added a solution 
of gallium chloride (281.7 mM in dry ethanol (EtOH)) (1.20 mL, 0.34 mmol) and triethylamine 
(0.15 mL, 1.05 mmol). The reaction mixture was stirred overnight at room temperature. The next 
day a yellow precipitate was filtered off, washed with dry methanol and dried in vacuo. Single-
crystal X-ray diffraction quality crystals were obtained by slow diffusion of diethyl ether into a 
methanolic solution of 1 (c ≈ 5 mg mL‒1). Yield: 0.10 g, 73%. Anal. Calcd for 
GaC13H15N5ClO2S·0.7H2O·0.5CH3OH (M 439.16 g mol‒1): C, 36.92; H, 4.22; N, 15.95; S, 7.30. 
Found: C, 37.10; H, 3.84; N, 15.61; S, 7.22. 1H NMR (500 MHz, DMSO-d6) δ 8.43 (s, 1H, H13), 
8.20 (t, J = 7.8 Hz, 1H, H5), 8.11 (s, 2H, H3), 7.80 (d, J = 7.6 Hz, 1H, H6), 7.56 (d, J = 7.8 Hz, 
1H, H4), 4.57 (d, J = 16.2 Hz, 1H, H7), 4.43 (d, J = 16.6 Hz, 1H, H7), 4.15 – 4.04 (m, 1H, H11), 
3.57 – 3.47 (m, 1H, H8), 3.15 – 3.04 (m, 1H, H11), 2.55 – 2.39 (m, 1H, H9), 2.09 – 1.97 (m, 1H, 
H10), 1.87 (m, 1H, H9), 1.66 (m, 1H, H10). 13C NMR (126 MHz, DMSO-d6) δ 179.99 (Cq, C14), 
173.25 (Cq, C12), 149.76 (Cq, C3), 143.90 (Cq, C1), 143.39 (CH , C5), 131.97 (CH, C13), 123.17 
(CH, C6), 123.13 (CH, C4), 69.47 (CH, C8), 59.69 (CH2, C7), 57.99(CH2, C11), 31.89 (CH2, C9), 
24.59 (CH2, C10). Solubility in water ≥18.28 mg mL‒1. ESI-MS (methanol), positive: m/z 374 
([M – Cl]+). IR (ATR, selected bands, v~max): 3298, 3082, 1738, 1636, 1411, 1371, 1171, 1079, 
1024, 653, 606 cm–1. 
 
2.2.2. [GaCl(dm-L-Pro-FTSC–2H)]·0.4H2O, 2·0.4H2O  
To a suspension of dm-L-Pro-FTSC (0.16 g, 0.48 mmol) in dry EtOH (10 mL) was added a 
solution of gallium chloride (281.7 mM in dry EtOH) (1.86 mL, 0.53 mmol) and triethylamine 
(0.22 mL, 1.59 mmol). A yellow, clear solution was formed, which was stirred overnight at 70 
°C. The next day the solution was cooled to room temperature and subjected to slow diethyl 
ether diffusion, after which a yellow precipitate appeared which was filtered, washed with dry 
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ethanol and dried in vacuo. X-ray diffraction quality crystals were obtained after slow diffusion 
of diethyl ether into an EtOH/water (20:1) solution of 2 (c ≈ 5 mg mL-1). Yield: 0.17 g, 79%. 
Anal. Calcd for GaC15H19N5O2SCl·0.4H2O (M 445.79 g mol-1): C, 40.41; H, 4.48; N, 15.71; S, 
7.19. Found: C, 40.45; H, 4.22; N, 15.34; S, 7.10. 1H NMR (500 MHz, DMSO-d6) δ 8.49 (s, 1H, 
H13), 8.20 (t, J = 7.8 Hz, 1H, H5), 7.78 (d, J = 7.8 Hz, 1H, H6), 7.56 (d, J = 7.8 Hz, 1H, H4), 4.57 
(d, J = 16.4 Hz, 1H, H7), 4.44 (d, J = 16.6 Hz, 1H, H7), 4.17 – 4.06 (m, 1H, H11), 3.53 (dd, J = 
10.7, 4.9 Hz, 1H, H8), 3.17 – 3.07 (m, 1H, H11), 2.48 – 2.41 (m, 1H, H9, overlapped with residual 
DMSO signal), 2.13 – 1.98 (m, 1H, H10), 1.93 – 1.83 (m, 1H, H9), 1.76 – 1.61 (m, 1H, H10). 13C 
NMR (126 MHz, DMSO-d6) δ 178.75 (Cq, C14), 173.23 (Cq, C12), 149.78 (Cq, C3), 144.03 (Cq, 
C1), 143.45 (CH, C5), 132.63 (CH, C13), 123.13 (CH, C4), 123.07 (CH, C6), 69.40 (CH, C8), 
59.68 (CH2, C7), 58.01(CH2, C11), 40.96 – 38,89 (2CH3, C16, C15, overlapped with residual 
DMSO signal) 31.94 (CH2, C9), 24.69 (CH2, C10). Solubility in water ≥11.67 mg mL-1. ESI-MS 
(methanol), positive: m/z 402 ([M – Cl]+). IR (ATR, selected bands, v~max): 2875, 1654, 1598, 
1361, 1294, 1251, 1212, 1144, 905, 764, 676, 625 cm–1. 
 
2.2.2. [FeCl(L-Pro-FTDA‒H)]Cl, 3  
To a solution of dm-L-Pro-FTSC (0.10 g, 0.30 mmol) in degassed methanol (5 mL) was added a 
solution of tetrapyridino-ferrous chloride (0.13 g, 0.30 mmol) in degassed methanol (5 mL). The 
color of the solution changed immediately from slightly yellow to dark blue and the reaction 
mixture was stirred overnight at room temperature. The reaction mixture was subjected to slow 
diethyl ether diffusion, using degassed diethyl ether. A blue-green precipitate was collected by 
filtration after several days. The mother liquor was allowed to stand for several days under an 
argon atmosphere. During this time its color changed from dark blue to purple and red-brown 
crystals appeared which were filtered and dried in vacuo. The obtained crystals were of X-ray 
diffraction quality. Yield: 25 mg, 16%. Anal. Calcd for C15H18FeN5O2SCl2·1.5H2O·MeOH (M 
518.22 g mol-1): C, 37.13; H, 4.87; N, 13.54; S, 6.18. Found: C, 36.85; H, 4.59; N, 13.19; S, 
6.33.  
 
2.3. Crystallographic Structure Determination  
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X-ray diffraction measurements were performed on a Bruker X8 APEXII CCD and Bruker D8-
Venture diffractometers. Single crystal was positioned at 35, 40 and 35 mm from the detector, 
and 950, 1964 and 4113 frames were measured, each for 10, 30 and 10 s over 1° scan width for 
1, 2 and 3, respectively. The data were processed using SAINT software.54 Crystal data, data 
collection parameters, and structure refinement details are given in Table 1. The structure was 
solved by direct methods and refined by full-matrix least-squares techniques. Non-hydrogen 
atoms were refined with anisotropic displacement parameters. Hydrogen atoms were inserted in 
calculated positions and refined with a riding model. The following computer programs and 
hardware were used: structure solution, SHELXS-97 and refinement, SHELXL-97;55 molecular 
diagrams, ORTEP;56 computer, Intel CoreDuo. 
 
2.4. Cell lines and culture conditions  
Human cervical carcinoma (HeLa), human alveolar basal adenocarcinoma (A549), human 
colorectal adenocarcinoma (LS174) cell lines and normal human fetal lung fibroblast cell line 
(MRC-5) were maintained as monolayer culture in the Roswell Park Memorial Institute (RPMI) 
1640 nutrient medium (Sigma Chemicals Co, USA). RPMI 1640 nutrient medium was prepared 
in sterile deionized water, supplemented with penicillin (192 U/mL), streptomycin (200 mg/mL), 
HEPES (25 mM), L-glutamine (3 mM) and 10% of heat-inactivated foetal calf serum (FCS) (pH 
7.2). The cells were grown at 37 ºC in 5% CO2 in a humidified air atmosphere.  
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Table 1. Crystal Data and Details of Data Collection for 1·0.175H2O, 2·H2O and 3 
Compound 1·0.175H2O 2·H2O 3 
empirical formula  C13H15.35ClGaN5O2.175S C15H21ClGaN5O3S C15H22Cl2FeN5O4S 
Fw 413.68 456.60 495.19 
space group C2 P21 P212121 
α, Å 30.5731(18) 8.2362(3) 7.4741(6) 
b, Å 7.6058(4) 21.2237(8) 10.322(1) 
c, Å 14.9814(8) 10.6393(4) 26.292(2) 
β, ° 113.394(2) 97.8388(12)  
V [Å3] 3197.3(3)  1842.40(12)  2028.3(3) 
Z 8 4 4 
λ [Å] 0.71073 0.71073 0.71073 
ρcalcd, g cm−3 1.719 1.646 1.622 
cryst size, mm3 0.18 × 0.02 × 0.02 0.16 × 0.12 × 0.05 0.15 × 0.15 × 0.01 
T [K] 100(2) 100(2) 100(2) 
µ, mm−1 2.036 1.778 1.142 
R1a 0.0636 0.0252 0.0400 
wR2b 0.1082 0.0539 0.1037 
GOFc 1.130 1.646 1.064 
Flack parameter 0.022(18) 
−0.004(4) 0.03(2) 
a
 R1 = Σ||Fo| − |Fc||/Σ|Fo|. b wR2 = {Σ[w(Fo2 − Fc2)2]/Σ[w(Fo2)2]}1/2. c GOF = {Σ[w(Fo2 − Fc2)2]/(n − p)}1/2, where n is the number of reflections and 
p is the total number of parameters refined.
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2.5. MTT assay  
Antiproliferative activity of the investigated complexes was determined using 3-(4,5-
dymethylthiazol-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich) assay.57 Cells 
were seeded into 96-well cell culture plates (Thermo Scientific Nunc™), at a cell density of 
4000 c/w (HeLa), 6000 c/w (A549), 7000 c/w (LS174), 5000 c/w (MRC-5) in 100 µL of 
culture medium. After 24 h of growth, cells were exposed to the serial dilutions of the tested 
complexes. The investigated compounds were dissolved in sterile water at a concentration of 
10 mM as stock solution, and prior the use diluted with nutrient medium to the desired final 
concentrations (up to 300 µM). Samples at each concentration were tested in triplicates. After 
incubation periods of 48 h, 20 µL of MTT solution (5 mg/mL in phosphate buffer solution, 
pH 7.2) were added to each well. Samples were incubated for 4 h at 37 °C, with 5% CO2 in a 
humidified atmosphere. Formazan crystals were dissolved in 100 µL of 10% sodium dodecyl 
sulfate (SDS). Absorbances were recorded after 24 h, on an enzyme-linked immunosorbent 
assay (ELISA) reader (ThermoLabsystems Multiskan EX 200–240 V), at the wavelength of 
570 nm. The IC50 value, defined as the concentration of the compound causing 50% cell 
growth inhibition, was estimated from the dose-response curves. 
2.6. pH-potentiometric measurements and calculations 
The exact concentration of the stock solutions of the L-Pro-FTSC was determined from pH-
potentiometric titrations by using the HYPERQUAD software.58 The pH-potentiometric 
measurements for the determination of the proton dissociation constants of the L-Pro-FTSC 
and the overall stability constants of the iron(II) and iron(III) complexes were carried out at 
298.0 ± 0.1 K in water and at an ionic strength of 0.10 M (KCl) to keep the activity 
coefficients constant. The titrations were performed with carbonate-free 0.10 M KOH 
solution. The concentrations of the base and the HCl were determined by pH-potentiometric 
titrations. An Orion 710A pH-meter equipped with a Metrohm combined electrode (type 
6.0234.100) and a Metrohm 665 Dosimat burette were used for the titrations. The electrode 
system was calibrated to the pH = −log[H+] scale according to the method suggested by Irving 
et al.59 The average water ionisation constant pKw is 13.76 ± 0.01, which corresponds well to 
the literature data.60 The reproducibility of the titration points included in the calculations was 
within 0.005 pH. The pH-metric titrations were performed in the pH range 2.0 − 11.5. The 
initial volume of the samples was 5.0 mL. The ligand concentration was 2 mM and metal ion-
to-ligand ratios of 1:1 − 1:4 were used. The accepted fitting of the titration curves was always 
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less than 0.01 mL. Samples were deoxygenated by bubbling purified argon through them for 
approximately 10 min prior to the measurements. Iron(II) was added to the samples in tightly 
closed vessels, which were prior completely deoxygenated by bubbling a stream of purified 
argon through them for ca. 20 min. Argon was also passed over the solutions during the 
titrations. 
 
The protonation constants of the L-Pro-FTSC were determined with the computer program 
HYPERQUAD.58 PSEQUAD61 was utilised to establish the stoichiometry of the complexes and to 
calculate the stability constants (logβ(MpLqHr)) using the literature data for iron(III) 
hydroxido complexes.62 β(MpLqHr) is defined for the general equilibrium pM + qL + rH  
MpLqHr as β(MpLqHr) = [MpLqHr]/[M]p[L]q[H]r, where M denotes the metal ion and L the 
completely deprotonated ligand. In all calculations exclusively titration data were used from 
experiments in which no precipitate was visible in the reaction mixture. 
 
2.7. UV–vis spectrophotometric and 1H NMR measurements 
A Hewlett Packard 8452A diode array spectrophotometer was used to record the UV–vis 
spectra in the 200 to 800 nm window. The path length was 1.0 or 2.0 cm. The 
spectrophotometric titrations were performed on samples of the L-Pro-FTSC alone or with 
iron(II) and iron(III) ions; the concentration of the ligand was ~100 µM and the metal-to-
ligand ratios were 1:1 and 1:2 over the pH range between 2 and 11.5 at an ionic strength of 
0.10 M (KCl) in water at 298.0 ± 0.1 K. For iron(II) samples, spectra were recorded under 
anaerobic conditions. Time-dependence of UV‒vis absorption spectra were recorded for the 
iron(III) − L-Pro-FTSC (1:1) system at pH 7.4 (10 mM HEPES) and 9.0 (10 mM CHES) 
under both aerobic and anaerobic conditions. 
 
The pH-dependent 1H NMR studies on the gallium(III) − L-Pro-FTSC (1:1) system were 
carried out on a Bruker Ultrashield 500 Plus instrument. 4,4-Dimethyl-4-silapentane-1-
sulfonic acid was used as an internal NMR standard and WATERGATE method was used to 
suppress the solvent resonance. L-Pro-FTSC was dissolved in a 10% (v/v) D2O/H2O mixture 
in a concentration of 1 mM at 298 K and ionic strength of 0.10 M (KCl). PSEQUAD61 was used 
to calculate the logβ values of the complexes [GaLH]2+ and [GaL]+ using the literature data 
for gallium(III) hydroxido complexes.63  
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3. Results and Discussion 
 
3.1. Synthesis and Characterisation of Metal Complexes 
The synthesis of L-Pro-FTSC and dm-L-Pro-FTSC was reported recently.49,51 The gallium(III) 
complexes [GaCl(L-Pro-FTSC–2H)]·0.7H2O·0.5CH3OH (1·0.7H2O·0.5CH3OH) and 
[GaCl(dm-L-Pro-FTSC–2H)]·0.4H2O (2·0.4H2O) were prepared by reaction of the 
corresponding ligand precursor with gallium(III) chloride in dry methanol and dry EtOH in 
the presence of trimethylamine as a base with yields of 73 and 79%, respectively. The 
structure and formulation of both complexes was confirmed by X-ray diffraction 
measurements (vide infra), one- and two-dimensional 1H and 13C NMR spectra and elemental 
analysis (see Experimental Section). ESI mass spectra of the gallium(III) complexes 1 and 2 
showed peaks with m/z 374 and 402, respectively, attributed to the [M − Cl]+ ion.  
 
The synthesis of the corresponding iron(III) complexes turned out to be not as straightforward 
as was the case for gallium(III) complexes 1 and 2. Reaction of iron(III) chloride with L-Pro-
FTSC in methanol in air led to a red solution and degradation of the ligand. ESI mass spectra 
of the resulting product mixture were difficult to interpret. The same reaction under inert 
atmosphere led to a blue solution, implying the reduction of iron(III) to iron(II) with 
concomitant oxidation of the ligand. Iron(II) complexes with L-Pro-FTSC and dm-L-Pro-
FTSC turned out to be extremely air sensitive and we were not able to obtain X-ray 
diffraction quality crystals for structure determination. The only isolated iron(III) complex 
was obtained by the reaction of trans-dichlorido(tetrapyridine)iron(II), also known as “yellow 
salt”, with dm-L-Pro-FTSC in deoxygenated methanol. The initially obtained dark-blue 
solution was subjected to slow diffusion of diethyl ether which resulted in the precipitation of 
a blue-green solid (iron(II)complex). The mother liquor was left to stand for several days 
under argon atmosphere. During this time the color of the solution changed from blue to 
violet and red-brown crystals appeared. It seems that an oxidation took place in the presence 
of small amounts of oxygen which entered the Schlenk tube in which the mother liquor was 
stored. The ligand and the metal center were oxidised giving the six-coordinate 
iron(III)thiadiazole complex 3, and its structure was confirmed by X-ray diffraction 
measurements and elemental analysis.  
 
3.2. X-ray crystallography  
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The results of X-ray diffraction studies of complexes 1‒3 are shown in Figures 1‒3. The 
complexes 1 and 2 crystallised in the noncentrosymmetric monoclinic space groups C2 and 
P21, respectively, while 3 in the noncentrosymmetric orthorhombic space group P212121. 
Unlike 3, the asymmetric unit of 1 and 2 consists of two crystallographically independent 
molecules of complexes. The proline-thiosemicarbazone hybrids L-Pro-FTSC and dm-L-Pro-
FTSC act as pentadentate doubly deprotonated ligands bonded to gallium(III) via pyridine 
nitrogen atom, imine nitrogen, thiolato sulfur atom, tertiary proline nitrogen, and proline 
carboxylate oxygen atom.   
 
Figure 1. ORTEP view of 1 with thermal displacement ellipsoids drawn at 50% probability 
level. Selected bond distances (Å) and bond angles (deg): Ga1a−N1a 2.026(6), Ga1a−N2a 
2.089(6), Ga1a−S1a 2.330(2), Ga1a−N5a 2.158(6) and Ga1a−O1a 1.977(5), Ga1a−Cl1a 
2.349(2), N2a−N3a 1.356(8), C7a−S1a 1.750(8); N1a−Ga1a−N2a 77.2(2), N2a−Ga1a−S1a 
82.68(18), N1a−Ga1a−N5a 79.8(2), N5a−Ga1a−O1a 81.5(2), N1a−Ga1a−O1a 86.9(2), 
N2a−Ga1a−O1a 89.3(2), S1a−Ga1a−O1a 92.57(16), O1a−Ga1a−Cl1a 170.47(17), 
N1a−Ga1a−Cl1a 89.60(17), N2a−Ga1a−Cl1a 98.59(17), N5a−Ga1a−Cl1a 89.20(17), 
S1a−Ga1a−Cl1a 93.77(7).   
 
This mode of coordination of (L-Pro-FTSC−2H)2− (dm-L-Pro-FTSC−2H)2− is well-
documented for copper(II) and zinc(II).49 
 
The coordination geometry of gallium(III) in 1 and 2 can be described as distorted octahedral 
with atoms N1a, N2a, S1a and N5a forming the equatorial plane and O1a and the chloride 
ligand Cl1a in axial positions (Figures 1 and 2). Upon coordination of the pentadentate ligand 
to gallium(III) four five-membered chelate rings are formed, three of which are essentially 
planar, while the fourth prolinic moiety adopts a half-chair conformation. The metal−TSC 
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bonds Ga1a−N1a and Ga1a−S1a (see legend to Figure 2) are significantly (> 3σ) shorter, 
while Ga1a−N2a bond is significantly longer than analogous interatomic distances in 
[GaL2][GaCl4] (HL = 2-acetylpyridine 4N-dimethylthiosemicarbazone).64     
 
As also in copper(II) and zinc(II) complexes with L-Pro-FTSC derivatives, the L-prolinate 
nitrogen atom N5a, in addition to C12a (or C14a), becomes a chiral center. The prolinate 
nitrogen atom and the asymmetric carbon atom adopt opposite configurations (SC,RN). Similar 
examples that resulted from coordination to metal ion or protonation of the proline nitrogen 
were reported, but they are rare.65   
 
Figure 2. ORTEP view of 2 with thermal displacement ellipsoids drawn at 50% probability 
level. Selected bond distances (Å) and bond angles (deg): Ga1a−N1a 1.9932(12), Ga1a−N2a 
2.0756(15), Ga1a−S1a 2.3304(4), Ga1a−N5a 2.1525(15) and Ga1a−O1a 1.9932(12), 
Ga1a−Cl1a 2.3909(4), N2a−N3a 1.345(2), C7a−S1a 1.755(2); N1a−Ga1a−N2a 77.06(6), 
N2a−Ga1a−S1a 82.94(5), N1a−Ga1a−N5a 79.37(6), N5a−Ga1a−O1a 81.88(6), 
N1a−Ga1a−O1a 89.94(6), N2a−Ga1a−O1a 89.65(6), S1a−Ga1a−O1a 90.46(4), 
O1a−Ga1a−Cl1a 171.51(4), N1a−Ga1a−Cl1a 88.75(4), N2a−Ga1a−Cl1a 98.22(4), 
N5a−Ga1a−Cl1a 89.64(4), S1a−Ga1a−Cl1a 93.640(16). 
 
A feature of note in the crystal structure of 1 is the formation of pairs of crystallographically 
independent molecules of complexes via strong hydrogen bonds of the type N‒H···N (see 
Figure S1). Other hydrogen bonds and their parameters are listed in Table S1. Complex 2 is 
not able to form this kind of pairs since by terminal dimethylation of the thiosemicarbazone 
moiety, the ligand loses its ability to act as proton donor through intermolecular hydrogen 
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bonding interactions. Hydrogen bonds which are still present in the crystal structure of 2 are 
given in Table S2. 
 
The new compound formed in the presence of iron(II/III) ions acts as a monodeprotonated 
pentadentate ligand providing three donor atoms for the equatorial plane completed by a 
chlorido ligand and a carboxylate ligand in an axial position. The latter plays a role of a 
bridging ligand with formation of a monocationic chain of six-coordinate iron(III) complex 3 
the global charge of which is counterbalanced by chloride ions.   
 
 
 
 
Figure 3. ORTEP view of a fragment of the crystal structure of 3 with thermal displacement 
ellipsoids drawn at 50% probability level showing the formation of a cationic polymeric 
chain. Selected bond distances (Å) and bond angles (deg): Fe−N1 2.134(3), Fe−N2 2.192(3), 
Fe−O2 2.072(3), Fe−N5 2.257(3) and Fe−O1i 2.053(3) (i denotes atom generated by 
symmetry transformation −x + 1, y + 0.5, −z + 0.5) and Fe−Cl1 2.3089(12), N2−N3 1.370(5), 
C6−S1 1.736(4), C7−S1 1.769(4); N1−Fe−N2 74.78(13), N1−Fe−N5 75.21(12), N5−Fe−O2 
79.11(11), N1−Fe−O2 86.79(11), N2−Fe−O2 83.41(12), Cl1−Fe−O2 91.87(9), O2−Fe−O1i 
169.06(12), Cl1−Fe−N2 108.31(10), Cl1−Fe−N5 101.35(9), N2−Fe−O1i 85.84(12), 
N1−Fe−O1i 88.43(12), N5−Fe−O1i 109.13(11).   
 
Oxidative addition of sulfur atom to the carbon atom of the neighbouring C=N bond led to 
formation of a five-membered thiadiazole ring. The formation of 1,3,4-thiadiazole ring via 
oxidative cyclisation of the thiosemicarbazones, dithiocarbazate or thiocarbohydrazones has 
been mainly observed in the presence of iron(III) and copper(II),66 although cyclisations 
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induced by silver(I), zinc(II), cadmium(II)67 and vanadium(IV/V)68 were also reported. 
Although the mechanism of ring formation has not been resolved yet, it certainly implies the 
coordination of the metal cation as a Lewis acid at the imine nitrogen atom, followed by the 
nucleophilic attack of thiol sulfur on the imine carbon and ring closure, and finally by the 
electron abstracting-dehydrogenation step.68c   
 
The lack of proton donor groups in the coordinated ligand reduces strongly the possibilities 
for hydrogen bonding in the crystal structure of 3. Only the two co-crystallised water 
molecules are involved in hydrogen bonding between themselves or by acting as proton 
donors in H-bond formation with chlorido ligand and chloride counterion (Table S3).   
 
3.3. Cytotoxicity of complexes 
Complexes 1‒3 were examined using the MTT assay in order to evaluate their 
antiproliferative activity in vitro. The analysis was performed in several human neoplastic cell 
lines (HeLa, A549, LS174), and one human fetal lung fibroblast cell line (MRC-5), which 
was used as a noncancerous model for the in vitro toxicity evaluation. The results are 
summarized in Table 2 in terms of IC50 values for the 48 h incubation period, which are 
calculated as mean values obtained from two to three independent experiments and quoted 
with their standard deviations. 
 
Cytotoxicity data indicate poor antiproliferative activity of 1 and 3 (IC50 > 300 µM), while 2 
showed higher cytotoxicity, with IC50 values being in the range of 50‒100 µM. The most 
sensitive cell line was shown to be the colorectal adenocarcinoma cell line LS174 (IC50(2)= 
54.5 ± 2.6 µM). Comparison of the data for ligand precursors, L-Pro-FTSC and dm-L-Pro-
FTSC, with those of 1 and 2 suggested that complexation with L-proline-thiosemicarbazone 
hybrids to gallium(III) showed better activity in vitro than complexation to iron. An 
explanation for this might be that the gallium(III)-TSC complex hydrolyses within the cell 
and the free TSC ligand gets released, which in turn chelates intracellular iron and possibly 
also sequesters iron from the RNR enzyme.48 Also, comparing the IC50 values of 1 and 2 has 
shown that dimethylation enhanced antiproliferative activity, which is in accordance with the 
previously reported studies which revealed how dimethylation of terminal aminogroup affects 
the cytotoxicity of ligands alone and/or complexes.49,69  
  
 
 
16 
 
 
Table 2. IC50 [µM] (mean ± SD) for 1‒3 and ligand precursors51 in human cancer and 
noncancerous cell lines after 48 h incubation time.  
Compound HeLa A549 LS174 MRC5 
1 >300 >300 >300 >300 
2 
3 
L-Pro-FTSC 
dm-L-Pro-FTSC 
122.0 ± 4.8 
>300 
>300 
224.6 ± 6.4 
103.1 ± 2.0 
268.5 ± 5.3 
>300 
204.3 ± 4.8 
54.5 ± 2.6 
54.5 ± 2.6 
n.d. 
n.d. 
87.0 ± 3.5 
87.0 ± 3.5 
>300 
178.4 ± 1.5 
 
3.4. Solution stability of the complexes 
Solution equilibrium studies on the complexation of L-Pro-FTSC as a reference compound 
with gallium(III), iron(II) and iron(III) ions were performed. Aqueous solution stability of the 
complexes formed in water was characterised and compared. The knowledge of speciation, 
especially at physiological pH, is a mandatory prerequisite for understanding the most 
plausible chemical forms of the complexes in solution which may be responsible for the 
biological activity. On the other hand, the binding ability of TSCs to iron(II) deserves a 
particular attention, since formation of an intracellular iron complex plays a crucial role in the 
suggested mechanism of inhibition of the RNR enzyme.70   
 
The proton dissociation processes of L-Pro-FTSC were already investigated in our recent 
work50 and the pKa values obtained here were found to be identical with the previously 
reported (Table 3). It is worth noting that L-Pro-FTSC is practically neutral at pH 7.4 (96% 
H2L and 4% HL‒, where L2‒ is the fully deprotonated form of the ligand precursor). However, 
H2L adopts a zwitterionic structure with COO‒ and NProH+, which explains its excellent 
aqueous-solubility. 1H NMR spectroscopy was found to be an adequate method to follow the 
complex formation processes of L-Pro-FTSC with gallium(III) ions. The 1H NMR spectra 
recorded at various pH values and 1:1 metal-to-ligand ratio (Figure 4a) reveal slow ligand-
exchange processes with respect to the NMR time scale as the chemical shifts of the protons 
of the ligand precursor and ligand coordinated to gallium(III) were observed separately. The 
integrated peak areas of the CH=N protons were converted to molar fractions of the ligand 
(Figure 4b). It can be seen from Figure 4b that complexes are formed only between pH 2 and 
pH 7 since no metal-bound ligand could be detected outside this range. Parallel to the 
decomposition of the gallium(III) complex with increasing pH, the upfield shift of the peaks 
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of the bound portion of the ligand is also observed indicating the deprotonation of the 
complex, thus the pKa was determined on the basis of this pH-dependent shift (Table 3). 
Comparing the pKa value of the complex with pK2 and pK3 of the ligand (pKa << pK2), the 
coordination of both the thiosemicarbazide and the Pro moieties is suggested in accordance 
with the result of the X-ray diffraction analysis of 1 (Figure 1). Thus formation of species 
[GaLH]2+ and [GaL]+ is assumed and their overall stability constants were calculated based on 
the 1H NMR data (Table 3). At excess ligand precursor, only species already identified in the 
measurements at 1:1 metal-to-ligand ratio were found. Therefore formation of bis-ligand 
complexes was excluded. The binding ability of L-Pro-FTSC to gallium(III) was compared to 
that of 2-formylpyridine thiosemicarbazone (FTSC), the simplest α(N)-pyridyl TSC, and its 
N-terminally dimethylated derivative (pyridine-2-carboxaldehyde N4,N4-
dimethylthiosemicarbazone, PTSC) via the calculated molar fractions of the ligands under 
identical conditions (Figure 4b). The L-Pro-FTSC forms higher stability complexes with 
gallium(III) ions than FTSC, though the complexes of both ligands decompose completely at 
the physiological pH. The decomposition is assumed to be even more pronounced upon 
dilution. This is presumably the reason for the similar IC50 values of these ligand precursors 
and their metal complexes (in the case of L-Pro-FTSC both are inactive against the tested 
human cancer cell lines, Table 2). On the other hand the N-terminal dimethylation 
significantly increases the solution stability of the gallium(III) complexes (c.f. molar fractions 
calculated for FTSC and PTSC), and higher stability is also expected for the complexes of 
dm-L-Pro-FTSC compared to that of L-Pro-FTSC. Most probably, the increased stability leads 
to the higher cytotoxicity of the gallium(III) complex (2) in comparison to that of the ligand 
precursor (Table 2). Thus the biological activity of the dm-L-Pro-FTSC complex is not 
governed simply by the ligand.  
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Figure 4. (a) Low field region of the 1H NMR spectra of the gallium(III) − L-Pro-FTSC (1:1) system 
recorded at indicated pH values, and the framed details of spectra with dashed line indicate the peaks 
assigned to the protons of the bound ligand; (b) pH-dependence of the 1H NMR chemical shifts of the 
CH=N peaks (×) with the fitted curve (dashed line) and the molar fractions of the bound ligand (▲) 
calculated on the basis of the integrals of these protons. Molar fractions calculated for metal-bound 
ligands FTSC and PTSC (solid lines) are shown for comparison based on the stability data taken from 
Ref. 69. [cL = 1.0 mM; Ga:L = 1:1; T = 298 K and I = 0.10 M (KCl); 10% (v/v) D2O]  
 
Table 3. Cumulative (logβ (MpLqHr)) and derived stability constants of the iron(II)−, 
iron(III)−, and gallium(III)− L-Pro-FTSC complexesa [T = 298 K and I = 0.10 M (KCl)] 
 
gallium(III)b iron(II)c iron(III)c 
logβ [MLH] 20.9(1) 17.84(6) 21.16(3) 
logβ [ML] 15.7(1) 11.97(5) 17.73(4) 
logβ [MLH
−1] ‒ 1.25(9) ‒ 
pKa [MLH] 5.2 5.87 3.43 
pMd 6.0 7.9 ‒ 
a Charges of the complexes are omitted for clarity. The numbers 
in parentheses are standard deviations. Proton dissociation 
constants of the ligand: pK1 = 1.86, pK2 = 8.78 and pK3 = 11.08 
taken from Ref. 50. b logβ values calculated from the 1H NMR 
δ values of the CH=N protons of the bound ligand. c logβ 
values determined by pH-potentiometry. d pM = −log [unbound 
metal ions] at pH 7.40; cL/cM = 10; cM = 0.001 mM. pM = 10.71 
for iron(II) ‒ FTSC; 11.6 for iron(II) ‒ Triapine; 12.9 for 
iron(II) ‒ PTSC systems based on data published in Ref. 69. 
 
Complex formation of L-Pro-FTSC with iron(II) and iron(III) in aqueous solution was 
investigated by pH-potentiometry and UV–vis spectrophotometry. Stoichiometries and 
cumulative stability constants of the metal complexes furnishing the best fits to the 
experimental pH-potentiometric data are listed in Table 3. Formation of only mono-ligand 
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species was detected in the case of the iron(II/III) ions similarly to gallium(III), copper(II),49 
zinc(II)48 and nickel(II).48 Representative titration curves (Figure 5) reveal that complex 
formation processes start at higher pH in the case of iron(II), consequently iron(II) complexes 
possess lower stability constants than the corresponding iron(III) species. It should be noted 
that the ligand was not able to keep iron(II) in solution at a metal-to-ligand ratio of 1:1 at pH 
> 10, and precipitation occurred. Most probably concomitant with the hydrolysis of the 
complex (i.e. formation of [FeLH‒1]), significant complex decomposition also takes place in 
the basic pH range and the hydrolysis of the non-bound metal ion resulted in precipitation of 
iron hydroxide. The iron(II) complex formation is witnessed by absorbance changes in the 
wavelength range 220 ‒ 430 nm at pH > 4 (Figure S1). Note that the formation of the green 
bis-ligand iron(II) complexes of TSCs is accompanied by the development of a typical broad 
absorption band with a maximum at ~520 nm,69 which was not seen for the iron(II) - L-Pro-
FTSC system. Most probably only mono-ligand iron(II) complexes are present in solution, in 
which the ligand acts as a pentadentate one, as also observed for the other metal ions studied. 
Binding through Npyr, N, S−, COO− and NPro donor atoms is assumed in the complex 
[Fe(II)L], while in [Fe(II)LH]+ the non-coordinating hydrazinic N is most probably 
protonated, and [Fe(II)LH‒1]‒ is a mixed hydroxido complex (= [Fe(II)L(OH)]‒). It should 
also be pointed out that α(N)-pyridyl TSCs generally form relatively stable octahedral bis-
ligand complexes with iron(II), in which the ligands coordinate via the Npyr,N,S− donor 
set.69,71 However, the presence of the Pro moiety in the ligand L-Pro-FTSC seems to hinder 
the simultaneous binding of two ligands to the metal ion. The binding ability of TSCs to 
iron(II) can be easily compared at pH 7.4 by the calculation of pM values (Table 3). The 
lower pM value obtained for L-Pro-FTSC than those for FTSC, Triapine or PTSC indicates a 
weaker chelating ability of the former, which might be responsible for the inactivity of the 
ligand L-Pro-FTSC against the cancer cells.  
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Figure 5. Representative pH-potentiometric titration curves for ligand L-Pro-FTSC (×), iron(II)– 
ligand system at 1:1 (◊) and 1:2 (♦), iron(III)– ligand system at 1:1 (∆) and 1:2 (▲) metal-to-ligand 
ratios [cL = 1.80 mM; T = 298 K and I = 0.10 M (KCl) in water]. Negative base equivalent values 
mean an excess amount of acid. 
 
The stability of the iron(II) complexes of L-Pro-FTSC was also compared to that for other 
divalent first-row transition metal ions which form complexes with similar coordination 
geometry (Figure 6) and it follows the well-known Irving–Williams sequence.  
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Figure 6. Cumulative stability constants (logβ) of the [MLH]+ (grey bars) and [ML] (white bars) 
complexes of bivalent metal ions formed with L-Pro-FTSC [T = 298 K and I = 0.10 M (KCl)]. Data 
for nickel(II), zinc(II) and copper(II) complexes are taken from Refs.49,51. 
 
The interaction of iron(III) with L-Pro-FTSC in aqueous solution was found to be rather 
complex, since a redox reaction was observed at pH ~7. Therefore, the stability constants 
(Table 3) were calculated from the data collected only at acidic pH values. Time-dependence 
of UV‒vis spectra recorded at pH 7.4 (Figure 7a) revealed a slow change of the absorbance 
values and no differences were observed in the presence or absence of oxygen (Figure 7b). In 
order to monitor the presence of iron(II) in solution a qualitative colour reaction was used, 
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namely 2,2-bipyridine (bpy) was added to the solution containing iron(III) and L-Pro-FTSC at 
pH 7.4 (Figure S2). Bpy is known to form stable complexes with iron(II) with characteristic 
red colour. Sample containing iron(II) and L-Pro-FTSC was also tested. The red coloured 
iron(II)-bpy complex was formed undoubtedly in the iron(III) ‒ L-Pro-FTSC system showing 
the presence of iron in oxidation sate +2, which is available for complexation with bpy. In the 
case of the iron(II) ‒ L-Pro-FTSC system the red colour is much less intense, bpy can not 
compete so efficiently with L-Pro-FTSC for the binding to iron(II). Most probably L-Pro-
FTSC is oxidised by iron(III) already at pH 7.4 according to the redox reaction shown in 
Scheme S1. Formation of the five-membered thiadiazole ring is probable and this oxidised 
product seems to be a weaker iron(II) binder than the original ligand precursor L-Pro-FTSC. 
Similar changes in UV–vis spectra were observed at pH 9, however, parallel to the slow redox 
reaction, decomposition of the complex also takes place resulting in the liberation of the 
ligand precursor and precipitation of iron(III)-hydroxides.  
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Figure 7. (a) Time-dependence of UV‒vis absorbance spectra of iron(III) − L-Pro-FTSC (1:1) system 
(solid lines) and spectrum of the ligand (dashed line) recorded at pH 7.4. (b) Absorbance values 
measured at 314 nm for the iron(III) − L-Pro-FTSC system under anaerobic conditions at pH 7.4 (+) 
and 9.0 (×) and under aerobic conditions at pH 7.4 (●) plotted against the reaction time (b). [cL = 100 
µM; Fe:L = 1:1; pH 7.4 (10 mM HEPES), pH 9.0 (10 mM CHES); T = 298 K and I = 0.10 M (KCl); l 
= 2 cm] 
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4. Concluding remarks 
Two gallium(III) complexes with pentadentate ligands, namely L-proline-thiosemicarbazone 
hybrids L-Pro-FTSC and its N-terminally dimethylated derivative, dm-L-Pro-FTSC, along 
with one iron(III) complex with a ligand derived from oxidation of L-Pro-FTSC, have been 
synthesised and spectroscopically characterised. In addition, their crystal structures were 
established by single crystal X-ray crystallography. The solution speciation of gallium(III), 
iron(II) and iron(III) complexes of L-Pro-FTSC has been characterized in pure aqueous 
solution via a combined approach using 1H NMR spectroscopy, pH-potentiometry and 
UV−vis spectrophotometry. The hybrid compounds were found to act as a pentadentate ligand 
in solution coordinating to gallium(III) via the Npyr, N, S−, COO− and NPro donor atoms. This 
binding mode was confirmed by X-ray crystallography in complexes 1 and 2. Compounds 
prepared in this work were tested for antiproliferative activity in different human cancer cell 
lines. The low iron(II) binding affinity of L-Pro-FTSC most probably contributes to the low 
antiproliferative effect of the ligand precursor. The gallium(III) speciation data revealing low 
aqueous solution stability of the complex of L-Pro-FTSC, explain the lack of antiproliferative 
activity for complex 1. Redox reaction between iron(III) and the ligands was detected at 
neutral and basic pH values resulting in the oxidation of the ligands possessing a five-
membered thiadiazole ring.  
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Synopsis 
Two gallium(III) complexes with L-proline-thiosemicarbazone hybrids have been synthesised 
and comprehensively characterised. Reaction of iron(III) with the terminally dimethylated L-
proline-thiosemicarbazone hybrid led to an oxidative cyclisation of the ligand and isolation of an 
iron(III) complex. The cytotoxicity of the new compounds was studied on three human cancer 
and one normal cell line, revealing no or low activity. The complexation reactions with iron(II), 
iron(III) and gallium(III) were studied in solution by using different methods. The low stability 
of the gallium(III) complexes at physiological pH and the low iron(II) binding affinity of the 
ligand precursors most probably contributes to the low antiproliferative activity of the studied 
substances.  
 
  
Highlights 
New gallium(III) and iron(III/II) complexes with L-proline-thiosemicarbazone hybrids were 
synthesised. 
Comprehensive  characterisation(1D/2D NMR, UV–vis, ESI MS and X-ray crystallography) 
of gallium(III) and iron(III) complexes. 
In vitro antiproliferative activity was evaluated. 
Solution stability of gallium(III) and iron(III/II) complexes investigated by pH-metry, 1H 
NMR- and UV‒vis spectroscopies. 
 
